Enlarge / The flu virus, showing the H and N proteins on its surface.CDC
An mRNA-based flu vaccine designed to offer long-lasting protection against a broad range of influenza viruses is now in a phase I clinical trial, the National Institutes of Health announced this week.
The trial brings the remarkable success of the mRNA vaccine platform to the long-standing efforts to develop a universal flu vaccine. Currently, health systems around the globe battle the seasonal scourge with shots that have to be reformulated each year to match circulating strains. This reformulation happens months before typical transmission, providing manufacturers time
→ Continue reading at Ars Technica